Communicators

are winners!

More News

12.04.2022
Phase I Clinical Trial of RECCE® 327 Advances to High Dose Level (2,000mg I.V)
11.04.2022
Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives
30.03.2022
Positive Safety Data from Fourth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
28.03.2022
RECCE: R&D Incentive Rebate Received
07.03.2022
Safety Committee Clears Next Dose - Phase I Clinical Study of RECCE® 327 (1,000mg I.V)
21.02.2022
Final Subjects Dosed in Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
08.02.2022
Positive Safety Data from Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
18.01.2022
Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
10.01.2022
Positive Safety Data from First Cohort of Phase I - Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
15.12.2021
Recce Pharmaceuticals: Patients to be Dosed in Phase I Intravenous Clinical Trial of RECCE® 327